Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of RDEA119, A MEK Inhibitor, in Advanced Cancer Patients

NCT00610194 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00610194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of RDEA119, A MEK Inhibitor, in Advanced Cancer Patients
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
November 28, 2007
Completion date
August 1, 2012
Enrollment
69 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer